Immune Biosolutions
Sherbrooke
About Immune Biosolutions
They are founded in 2012 by three entrepreneurial scientists, hoping to devise a full-proof platform for the discovery of clinically-relevant antibodies. Over the years, they have been supported by many prestigious entrepreneurship and scientific awards to create our Nebula Antibody platform and have substantiated this platform through several collaborations with various North American and European pharmaceutical partners. We have also produced over 350 commercial antibodies and submitted several patents for our technologies. In 2015, they took the bold step of initiating their own antibody pipeline, with a primary focus on cancer and gastrointestinal health. Thus far we have advanced 4 candidates to late stages of discovery.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $11.1M
- Funding stage: Seed
- Last round: Grant (Mar 2021)
- Website: immunebiosolutions.com
- Phone: 1-819-564-5283
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immune-biosolutions-139795 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.